|Bid||7.15 x 2900|
|Ask||7.20 x 2200|
|Day's range||6.49 - 7.35|
|52-week range||3.95 - 26.12|
|Beta (5Y monthly)||2.83|
|PE ratio (TTM)||N/A|
|Earnings date||30 Apr 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.00|
Millions of Americans who would like to lower their risk of a heart attack could have a new, low-cost option to help them. On Friday, the FDA approved 1 gram Icosapent Ethyl Capsules from Hikma Pharmaceuticals (OTC: HKMPY). Hikma's capsules are the generic equivalent of Vascepa from Amarin (NASDAQ: AMRN), a branded fish oil product expected to drive billions in annual sales.
HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19
DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of.
Irish biopharmaceutical company Amarin (NASDAQ: AMRN) posted record revenue of $155 million in its first-quarter earnings reported April 30, marking an 112% year-over-year increase for a net loss of $20.6 million, or $0.06 per share. The company's sole product, Vascepa, is a drug derived from fish oil. It was approved by the U.S. Food and Drug Administration (FDA) as an add-on with statin therapy to lower the risk of heart attack, stroke, and cardiovascular disease and to bring down high levels of triglycerides in adult patients.
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified.
Initial public offerings, or IPOs, usually garner lots of attention. IPOs carry tremendous amounts of risk, and trading publicly begins a new phase in the company's life. Drug development firms add in layers of additional risk -- clinical trial efficacy and safety risks, regulatory risk such as approval by the U.S. Food and Drug Administration (FDA), and reimbursement risk.
Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.
Image source: The Motley Fool. Amarin Corporation plc (NASDAQ: AMRN)Q1 2020 Earnings CallApr 30, 2020, 7:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Amarin Corporation's Conference Call to discuss its Preliminary First Quarter Financial Results and Operational Updates.
Amarin Corporation plc (AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2020 financial results and provide an operational update on Thursday, April 30, 2020, at 7:30 a.m. ET. Amarin will host a conference call April 30, 2020, at 7:30 a.m. ET to discuss this information.
Amarin Corporation plc (AMRN) today announced that it will host a conference call with management on Monday, April 13, 2020, at 4:30 p.m. ET to discuss the company's preliminary first quarter 2020 financial results and provide an operational update on matters including COVID-19, the company’s planned appeal in the ongoing patent litigation related to VASCEPA® (icosapent ethyl) in the United States and plans for international expansion. This conference call is not intended to replace the regularly scheduled call Amarin plans to hold in connection with its reporting of first quarter 2020 results. The conference call will take place on April 13, 2020, at 4:30 p.m. ET.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc.
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc.
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has opened an investigation into Amarin Corp. plc (AMRN) and certain of its officers for potential securities fraud. Amarin is a pharmaceutical company that has brought one drug to market, Vascepa®, which is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Beginning in 2016, several would-be generic manufacturers filed applications with the U.S. Food and Drug Administration seeking to market generic versions of Vascepa®.
DUBLIN, Ireland and BRIDGEWATER, N.J., March 31, 2020 -- Amarin Corporation plc (NASDAQ:AMRN), hosted a webcast yesterday to discuss important data with study authors who.
Amarin Corporation plc (AMRN) today commented on the United States District Court for the District of Nevada’s ruling in favor of the generic companies in the company’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise. Based on Amarin’s review of U.S. Food and Drug Administration’s (FDA’s) website, an ANDA for VASCEPA has not been approved, which would be required for launch of a generic product in the United States. The company thus does not believe there is an impending generic launch by the litigants that would compete with VASCEPA at this time.
Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular.